Aptorum Group Limited - Class A Ordinary Shares (APM) News
Filter APM News Items
APM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APM News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest APM News From Around the Web
Below are the latest news stories about APTORUM GROUP LTD that investors may wish to consider to help them evaluate APM as an investment opportunity.
Aptorum Group to Issue 1.5 Million Class A SharesAptorum Group ( (APM) ) has provided an update. Aptorum Group Limited, a Cayman Islands exempted company, has announced the issuance and offering of 1,535,000 Class A ordinary shares. This move is facilitated through a Securities Purchase Agreement and is in compliance with a registration statement filed with the U.S. Securities and Exchange Commission. The issuance of these shares is expected to enhance Aptorum Group’s capital structure and potentially impact its market positioning by providing |
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct OfferingNEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at |
Why Aptorum Group (APM) Jumped Nearly 300% at Pre-Market TradingBiopharmaceutical company Aptorum Group Ltd. (NASDAQ:APM) saw its pre-market stock price on Tuesday jump by nearly 300 percent, with investor optimism fueled by the company’s improved earnings performance during the first half of the year. As of 8:49 AM, the company’s share price was already trading as much as 270.48 percent at $5.02 apiece. Last […] |
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024NEW YORK, December 20, 2024--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. |
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business UpdateNEW YORK & LONDON, April 30, 2024--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. |
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don’t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That’s why it’s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla |
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy BusinessNEW YORK & LONDON, March 06, 2024--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Apto |